Psoriasis - severe chronic plaque psoriasis

The PBS subsidises biological agents for patients with severe chronic plaque psoriasis.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with biological agents under the National Health Act 1953, section 85 and section 100 for patients with severe chronic plaque psoriasis.

Where the term ‘biological agent’ appears, it refers to:

  • adalimumab
  • etanercept
  • guselkumab
  • infliximab
  • ixekizumab
  • risankizumab
  • secukinumab
  • tildrakizumab
  • ustekinumab.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing biological agents.

Section 100 arrangements

Infliximab i.v.

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Toxicity and severity descriptors

When demonstrating a patient’s intolerance to prior treatment, use the severe chronic plaque psoriasis toxicity and severity descriptors with the authority application.

Treatment specifics

To be eligible for PBS-subsidised treatment with a biological agent, patients must be treated by a dermatologist.

Authority applications

Patients 18 years of age or older

Applying for initial treatment

Apply for initial authority approval to prescribe PBS-subsidised biological agents to treat severe chronic plaque psoriasis in writing and either:

All written applications must include the completed:

Applying for initial grandfather treatment

For patients who received non-PBS-subsidised risankizumab treatment before 1 August 2022 for severe chronic plaque psoriasis, apply for initial grandfather authority approval in writing and either:

All written applications must include the completed:

Applying for change or recommencement of treatment

Apply to change or recommence authority approval to prescribe PBS-subsidised biological agents to treat adult patients with severe chronic plaque psoriasis in writing and either:

All written applications must include the completed:

You can also use this authority application form to submit a demonstration of response to the current PBS-subsidised treatment.

Applying for continuing treatment

Apply for continuing authority approval to prescribe PBS-subsidised biological agents to treat adult patients with severe chronic plaque psoriasis in writing and either:

All written applications must include the completed:

After we approve the first application for continuing treatment, subsequent continuing treatment with PBS-subsidised biosimilar brands of biological agents are Authority Required (Streamlined). You don’t need authority approval from us for the listed quantity and repeats.

Patients under 18 years

Applying for initial, change, recommencement, re-treatment, course completion or demonstration of response treatment

Apply for initial, change, recommencement, re-treatment, course completion (etanercept only) or demonstration of response (ustekinumab only) authority approval to prescribe PBS-subsidised etanercept or ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis in writing and either:

All written applications must include the completed:

You can also use these authority application forms to submit a demonstration of response to the current PBS-subsidised treatment.

Applying for continuing treatment

Apply for continuing authority approval to prescribe PBS-subsidised ustekinumab to treat patients under 18 years with severe chronic plaque psoriasis in writing and either:

All written applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 October 2022